Literature DB >> 8828547

Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease.

D P Metz1, A S Bacon, S Holgate, S L Lightman.   

Abstract

BACKGROUND: Chronic allergic conjunctivitis comprises a spectrum of diseases including atopic keratoconjunctivitis, atopic blepharoconjunctivitis, vernal keratoconjunctivitis, and contact lens-associated giant pupillary conjunctivitis. Each condition is characterized by a complex immunopathology with a mixed cellular infiltrate. Treatment with conventional mast cell stabilizers is often unsatisfactory, and therapy depends heavily on topical corticosteroids.
OBJECTIVE: Recent evidence suggests that T lymphocytes play an important role in mediating the immunopathology seen in the chronic allergic response in the skin and the lungs.
METHODS: We have therefore investigated the prevalence of T cells and their subsets in the different chronic allergic eye conditions by means of immunohistochemistry.
RESULTS: We found significantly increased numbers of CD4+, CD45RO+, and HLA-DR+ T cells in the conjunctiva of patients with atopic and vernal keratoconjunctivitis and giant papillary conjunctivitis, with a corresponding upregulation of markers present on antigen presenting cells.
CONCLUSIONS: These findings suggest that like allergic conditions in the skin and lungs, CD4+ memory T cells are involved in the regulation of the immunopathology of chronic allergic eye responses. Further characterization of these T cells will provide the information necessary for future immunotherapeutic interventions.

Entities:  

Mesh:

Year:  1996        PMID: 8828547     DOI: 10.1016/s0091-6749(96)70103-3

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  17 in total

Review 1.  Recent patents and emerging therapeutics in the treatment of allergic conjunctivitis.

Authors:  Gyan P Mishra; Viral Tamboli; Jwala Jwala; Ashim K Mitra
Journal:  Recent Pat Inflamm Allergy Drug Discov       Date:  2011-01

Review 2.  Allergic eye disease mechanisms.

Authors:  J I McGill; S T Holgate; M K Church; D F Anderson; A Bacon
Journal:  Br J Ophthalmol       Date:  1998-10       Impact factor: 4.638

Review 3.  [Ocular allergies].

Authors:  E M Messmer
Journal:  Ophthalmologe       Date:  2005-05       Impact factor: 1.059

4.  Cellular changes in tears associated with keratoconjunctival responses induced by nasal allergy.

Authors:  Z Pelikan
Journal:  Eye (Lond)       Date:  2014-01-17       Impact factor: 3.775

5.  Th1- and Th2-type cytokines in chronic ocular allergy.

Authors:  Andrea Leonardi; Iva A Fregona; Mario Plebani; Antonio G Secchi; Virginia L Calder
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

6.  Conjunctival macrophages act as antigen-presenting cells in the conjunctiva during the development of experimental allergic conjunctivitis.

Authors:  Waka Ishida; Ken Fukuda; Mina Kajisako; Ayako Takahashi; Tamaki Sumi; Nico van Rooijen; Atsuki Fukushima
Journal:  Mol Vis       Date:  2010-07-10       Impact factor: 2.367

Review 7.  An Update on the Therapeutic Approach to Vernal Keratoconjunctivitis.

Authors:  Susanna Esposito; Giulia Fior; Alessandro Mori; Silvia Osnaghi; Daniele Ghiglioni
Journal:  Paediatr Drugs       Date:  2016-10       Impact factor: 3.022

Review 8.  New twists to an old story: novel concepts in the pathogenesis of allergic eye disease.

Authors:  Daniel R Saban; Virginia Calder; Chuan-Hui Kuo; Nancy J Reyes; Darlene A Dartt; Santa J Ono; Jerry Y Niederkorn
Journal:  Curr Eye Res       Date:  2013-01-02       Impact factor: 2.424

9.  Concentration of soluble interleukin-6 receptors in tears of allergic conjunctival disease patients.

Authors:  Jun Shoji; Atsuri Kawaguchi; Aki Gotoh; Noriko Inada; Mitsuru Sawa
Journal:  Jpn J Ophthalmol       Date:  2007-10-05       Impact factor: 2.447

10.  Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis.

Authors:  M Daniell; M Constantinou; H T Vu; H R Taylor
Journal:  Br J Ophthalmol       Date:  2006-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.